Viscum album L. extracts in breast and gynaecological cancers: A systematic review of clinical and preclinical research

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Kienle, Gunver S ^a   Glockmann, Anja ^a   Schink, Michael ^b   Kiene, Helmut ^a  

^a Institut fur angewandte Erkenntnistheorie und medizinische Methodologie e V   (Germany)

^b Verein Filderklinik EV Research Department   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AVISCUMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXYCYCLINE; GEMCITABINE; HELIXOR M; IFOSFAMIDE; ISCADOR M; LENTINAN; PLACEBO; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT; VISCUM ALBUM LECTIN; VISCUM FRAXINI; PLANT EXTRACT;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; CYTOTOXICITY; DATA BASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; GENITAL TRACT CANCER; GRANULOCYTE FUNCTION; GYNECOLOGIC CANCER; HUMAN; LEUKOPENIA; LEUKOPOIESIS; LUNG CANCER; LYMPHOCYTE COUNT; MEDICAL LITERATURE; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PAIN; PLEURA EFFUSION; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RETCHING; SAMPLE SIZE; SIDE EFFECT; STOMATITIS; SYSTEMATIC REVIEW; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERUS CANCER; VOMITING; ANIMAL; BREAST TUMOR; DRUG SCREENING; FEMALE; FEMALE GENITAL TRACT TUMOR; PHYTOTHERAPY; REVIEW; VISCUM ALBUM;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MISTLETOE; PHYTOTHERAPY; PLANT EXTRACTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 68349116044     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-79     Document Type: Article

References (166)

1. Estimates of the cancer incidence and mortality in Europe in 2006. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle, Ann Oncol 2007 18 581 592 10.1093/annonc/mdl498 17287242 (Pubitemid 46359643)
2. Stat Bite: Number of Cancer Survivors by Site, 2003. J Natl Cancer Inst 2006 98 21 1514
3. Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. PA Fasching F Thiel K Nicolaisen-Murmann C Rauh J Engel MP Lux MW Beckmann MR Bani, Support Care Cancer 2007 55 1277 1284 10.1007/s00520-007-0231-1 (Pubitemid 47583442)
4. The use of complementary and alternative medicines among patients with locally advanced breast cancer - a descriptive study. LK Helyer S Chin BK Chuim B Fitzgerald S Verma E Rakovitch G Dranitsaris M Clemons, BMC Cancer 2006 6 39 16504038 10.1186/1471-2407-6-39 (Pubitemid 43842128)
5. Complementary and alternative medicine use among women with breast cancer. LM DiGianni JE Garber EP WIner, J Clin Oncol 2002 20 34s 38s 12235222
6. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. HS Boon F Olatunde SM Zick, BMC Woman's Health 2007 7 4 10.1186/1472-6874-7-4 (Pubitemid 46585636)
7. Complementary and alternative medicine use in breast cancer patients in Europe. A Molassiotis JA Scott N Kearney D Pud M Magri S Selvekerova I Bruyns P Fernandez-Ortega V Panteli A Margulies G Gudmundsdottir L Milovics G Ozden N Platin E Patiraki, Support Care Cancer 2006 14 260 267 10.1007/s00520-005-0883-7 16143871 (Pubitemid 43247930)
8. Complementary and alternative medicine use in patients with gynecological cancers in Europe. A Molassiotis M Browall L Milovics V Panteli E Patiraki P Fernandez-Ortega, International Journal of Gynecological Cancer 2006 16 219 224 10.1111/j.1525-1438.2006.00309.x 16515594
9. Plants as a source of anti-cancer agents. GM Cragg DJ Newman, Ethnopharmacology. Encyclopedia of Life Support Systems (EOLSS), developed under the Auspices of the UNESCO Oxford, UK, Eolss Publishers, Elisabetsky E, Etkin NL, 2006 http://www.eolss.net
10. Use of complementary and alternative medicine in cancer patients: a European survey. A Molassiotis P Fernandez-Ortega D Pud G Ozden JA Scott V Panteli A Margulies M Browall M Magri S Selvekerova E Madsen L Milovics I Bruyns G Gudmundsdottir S Hummerston AM Ahmad N Platin N Kearney E Patiraki, Ann Oncol 2005 16 655 663 10.1093/annonc/mdi110 15699021 (Pubitemid 40613334)
11. The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes. Y Endo K Tsurugi H Franz, FEBS Letters 1988 231 378 380 10.1016/0014-5793(88)80853-6 3360143
12. Action of viscumin, a toxic lectin from mistletoe, on cells in culture. F Stirpe K Sandvig S Olsnes A Pihl, The Journal of Biological Chemistry 1982 257 13271 13277 7142145
13. Ribosome-inactivating proteins from plants: present status and future prospects. F Stirpe L Barbieri MG Battelli M Soria DA Lappi, Biotechnology (N Y). 1992 10 4 405 412 10.1038/nbt0492-405 1368484
14. Isolation and partial characterization of a small chitin-binding lectin from mistletoe (Viscum album). WJ Peumans P Verhaert U Pfüller EJM Van Damme, FEBS Letters 1996 396 261 265 10.1016/0014-5793(96)01108-8 8914999 (Pubitemid 26377836)
15. Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from Viscum album extract. CY Klett FA Anderer, Arzneimittelforschung. 1989 39 12 1580 1585 2624609
16. A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. EA Mueller FA Anderer, Cancer Immunol Immunother 1990 32 221 227 10.1007/BF01741704 2124513
17. Anti-inflammatory and antinociceptive activity of flavonoids isolated from VISCUM ALBUM ssp. ALBUM. DD Orhan E Küpeli E Yesilada F Ergun, Z Naturforsch C. 2006 61 1-2 26 30 16610212
18. Characterization of membrane vesicles in plant extracts. K Winkler G Leneweit R Schubert, Colloids and surfaces B, Biointerfaces 2005 45 57 65 10.1016/j.colsurfb.2005.07.006 16125916 (Pubitemid 41266921)
19. Solubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L. S Jager K Winkler U Pfuller A Scheffler, Planta Med 2007 73 157 162 10.1055/s-2007-967106 17415876 (Pubitemid 46910434)
20. GS Kienle H Kiene, Die Mistel in der Onkologie - Fakten und konzeptionelle Grundlagen Stuttgart, New York: Schattauer Verlag 2003
21. A Büssing (ed), Mistletoe. The Genus Viscum Amsterdam: Hardwood Academic Publishers 2000
22. Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata). J Eggenschwiler BL von B Stritt D Pruntsch M Ramos K Urech L Rist AP Simoes-Wust A Viviani, BMC Complement Altern Med 2007 7 14 17493268 10.1186/1472-6882-7-14 (Pubitemid 46864919)
23. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. A Büssing M Schietzel, Anticancer Res 1999 19 23 28 10226520
24. Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes. U Elsässer-Beile S Lusebrink U Grussenmeyer U Wetterauer W Schultze-Seemann, Arzneimittelforschung. 1998 48 12 1185 1189 9893935
25. The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. U Valentiner U Pfüller C Baum U Schumacher, Toxicology 2002 171 187 199 10.1016/S0300-483X(01)00581-9 11836024 (Pubitemid 34142492)
26. Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. I Siegle P Fritz M McClellan S Gutzeit TE Murdter, Anticancer Res 2001 21 2687 2691 11724340
27. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. H Bantel IH Engels W Voelter K Schulze-Osthoff S Wesselborg, Cancer Research 1999 59 2083 2090 10232592
28. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: Chemical specificity of target cell recognition. EA Mueller FA Anderer, Cancer Research 1990 50 3646 3651 1692765
29. Enhancement of MHC-unrestricted cytotoxic activity of human CD56+CD3- natural killer (NK) cells and CD+T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets. HG Zhu TM Zollner A Klein-Franke FA Anderer, J Cancer Res Clin Oncol 1994 383 388 10.1007/BF01240135 7514604 (Pubitemid 24159229)
30. Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. W-B Park SY Lyu JH Kim SH Choi HK Chung SH Ahn SY Hong TJ Yoon MJ Choi, Cancer Biother Radiopharm 2001 16 439 447 10.1089/108497801753354348 11776761
31. Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins. JP Van Huyen J Bayry S Delignat AT Gaston O Michel P Bruneval MD Kazatchkine A Nicoletti SV Kaveri, Mol Med 2002 8 600 606 12477970
32. Phase I trial on intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. P Schöffski S Riggert P Fumoleau M Campone O Bolte S Marreaud D Lacombe B Baron M Herold H Zwierzina K Wilhelm-Ogunbiyi H Lentzen C Twelves European Organization for Research and Treatment of Cancer New Drug Development Group, Ann Oncol 2004 15 1816 1824 10.1093/annonc/mdh469 15550588 (Pubitemid 40017162)
33. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. P Schöffski I Breidenbach J Krauter O Bolte M Stadler A Ganser K Wilhelm-Ogunbiyi H Lentzen, Eur J Cancer 2005 41 1431 1438 10.1016/j.ejca.2005.03.019 15913988 (Pubitemid 40826467)
34. Mistletoe in cancer - a systematic review on controlled clinical trials. GS Kienle F Berrino A Büssing E Portalupi S Rosenzweig H Kiene, Eur J Med Res 2003 8 109 119 12730032
35. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. H Stauder E-D Kreuser, Onkologie 2002 25 374 380 10.1159/000066058 12232491
36. Complementary Cancer Therapy: A Systematic Review of Prospective Clinical Trials on Anthroposophic Mistletoe Extracts. GS Kienle H Kiene, Eur J Med Res 2007 12 103 119 17507307
37. Mistletoe for cancer? A systematic review of randomized clincial trials. E Ernst K Schmidt MK Steuer-Vogt, Int J Cancer 2003 107 262 267 10.1002/ijc.11386 12949804 (Pubitemid 37152907)
38. Mistletoe therapy in oncology. MA Horneber G Bueschel R Huber K Linde M Rostock, Cochrane Database Syst Rev 2008 CD003297 18425885
39. Misteltherapie als begleitende Behandlung zur Reduktion der Toxizität der Chemotherapie maligner Erkrankungen. AM Lange-Lindberg M Velasco Garrido R Busse, GMS Health Technol Assess 2006; 2:Doc18 (20060919) 2006
40. KS Khan G ter Riet J Glanville AJ Sowden J Kleijnen, Undertaking Systematic Reviews of Research on Effectiveness. CRD'S Guidance for those Carrying Out or Commissioning Reviews. CRD Report Number 4 University of York: NHS Centre for Reviews and Dissemination 2 2001
41. Mistletoe treatment for cancer - review of controlled trials in humans. J Kleijnen P Knipschild, Phytomedicine 1994 1 255 260
42. Iscador QuS and human recombinant interferon alpha (Intron A) in cervical intraepithelial neoplasia (CIN). R Jach A Basta, Przeglad Lekarski 1999 56 86 88 10375935
43. Role of immunomodulatory treatment with Iscador QuS and Intron A of women with CIN1 with concurrent HPV infection. R Jach A Basta A Szczudrawa, Ginekol Pol 2003 74 729 735 14674116
44. Phase I study of mistletoe extract/gemcitabine combination treatment in patients with advanced solid tumors. PJ Mansky DB Wallerstedt BP Monahan C Lee T Sannes J Stagl MA Blackman SL Swain J Grem, Onkologie 2008 31 200 10.1159/000119121 18418023 (Pubitemid 351700545)
45. Zusammenhang der NK-Zellaktivität gegen autologe Tumor- und K562-Zellen mit dem klinischen Verlauf unter Misteltherapie. M Schink W Tröger A Goyert H Scheuerecker K Selbmann F Glaser, Forsch Komplementärmed 2006 13 147 155 10.1159/000092624 (Pubitemid 44014993)
46. Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. G Bar-Sela H Goldberg D Beck A Amit A Kuten, Anticancer Res 2006 26 709 714 16739342
47. Additional therapy with mistletoe extracts in breast cancer patients receiving chemotherapy: a prospective randomized open label pilot study. W Tröger M Matijaevic Z drale N Tisma S Jezdic, Die Mistel in der Tumortherapie 2. - Aktueller Stand der Forschung und klinische Anwendung Essen, KVC-Verlag, Scheer R, Alban S, Becker H, Holzgrabe U, Kemper FH, Kreis W, Matthes H, Schilcher H, 2009 509 521
48. Modulation of chemotherapy-associated immunosuppression by intravenous application of Viscum album L. extract (Iscador): a randomised physe II study. A Büssing U Brückner U Enser-Weis M Schnelle A Schumann M Schietzel W Hatzmann J Hackmann, European Journal for Integrative Medicine 2008 1 S44 S54
49. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). R Grossarth-Maticek R Ziegler, Eur J Med Res 2008 13 107 120 18499556
50. Prospective controlled cohort studies on long-term therapy of ovarian cancer patients with mistletoe (Viscum album L.) extracts Iscador. R Grossarth-Maticek R Ziegler, Arzneimittelforschung 2007 57 10 665 678 18074761 (Pubitemid 350075413)
51. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). R Grossarth-Maticek R Ziegler, Forsch Komplementärmed 2007 14 140 147 10.1159/000102956 (Pubitemid 47013381)
52. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador) - Supplementary materials. R Grossarth-Maticek R Ziegler, 2006 10.1159/000095378 (Pubitemid 44641775)
53. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). R Grossarth-Maticek R Ziegler, Forsch Komplementärmed 2006 13 285 292 10.1159/000095378 (Pubitemid 44641775)
54. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. VF Semiglasov VV Stepula A Dudov J Schnitker U Mengs, Anticancer Res 2006 26 1519 1530 16619567
55. Signifikant höherer Anteil aktivierter NK-Zellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiven randomisierten doppelblinden Studie. L Auerbach V Dostal I Václavik- Fleck E Kubista A Rosenberger S Rieger W Tröger JM Schierholz, Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung Essen, KVC Verlag, Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, 2005 543 554
56. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. BK Piao YX Wang GR Xie U Mansmann H Matthes J Beuth HS Lin, Anticancer Res 2004 24 303 309 15015612
57. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. VF Semiglasov VV Stepula A Dudov W Lehmacher U Mengs, Anticancer Res 2004 24 1293 1302 15154663
58. Evaluation of the quality of life in breast cancer patients undergoing lectin standardized mistletoe therapy. E Borrelli, Minerva Medica 2001 92 105 107
59. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. R Grossarth-Maticek H Kiene S Baumgartner R Ziegler, Altern Ther Health Med 2001 7 57 78 11347286
60. Comparative study on the effects of a Viscum album (L.) extract (mistletoe) and doxycycline for pleurodesis in patients with malignant pleural effusion. 51th Meeting of The Korean Association of Internal Medicine. Translation by Helixor Heilmittel GmbH. M-H Kim Y-K Park S-H Lee S-C Kim S-Y Lee C-H Kim Y-K Kim K-H Kim H-S Moon J-S Song S-H Park, Korean Journal of Medicine 1999 57 S121
61. Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema). B-M Heiny, Krebsmedizin 1991 12 1 14
62. Prospektive Studie beim radikal operierten Mammakarzinom mit Polychemotherapie, Helixor und unbehandelter Kontrolle. J Gutsch H Berger G Scholz H Denck, Dtsch Zschr Onkol 1988 94 100
63. Modulation der subjektiven und objektiven Toxizität einer aggressiven Chemotherapie mit Helixor. Unpublished Report. O Lange G Scholz J Gutsch, 1985
64. Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom -Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit. A Loewe-Mesch JH Kuehn K Borho U Abel C Bauer I Gerhard A Schneeweiss C Sohn T Strowitzki C Hagens, Forsch Komplementärmed 2008 15 22 30 10.1159/000112860
65. Prevention of surgery-induced depression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. A Büssing M Bischof W Hatzmann F Bartsch D Soto-Vera E-M Fronk M Gmeindl GM Stein, Anticancer Res 2005 25 4753 4758 16334172
66. -30 Jahre Erfahrung mit der Misteltherapie an öffentlichen Krankenanstalten. G Salzer, Misteltherapie. Eine Antwort auf die Herausforderung Krebs Stuttgart, Verlag Freies Geistesleben, Leroi R, 1987 173 215
67. Nachbehandlung bestrahlter Genitalkarzinome mit dem Viscum-album- Präparat "Iscador". Ch Fellmer KE Fellmer, Krebsarzt 1966 21 174 185
68. ber Zusatzbehandlung beim weiblichen Genitalkarzinom. A Majewski W Bentele, Zentralbl Gynäkol 1963 85 696 700
69. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. J Beuth B Schneider JM Schierholz, Anticancer Res 2008 28 523 528 18383896
70. Wirksamkeit und Sicherheit der komplementären Langzeitbehandlung mit einem standardisierten Extrakt aus Europäischer Mistel (Viscum album L.) zusätzlich zur konventionellen adjuvanten onkologischen Therapie bei primärem, nicht metastasiertem Mammakarzinom. Ergebnisse einer multizentrischen, komparativen, epidemiologischen Kohortenstudie in Deutschland und der Schweiz. PR Bock WE Friedel J Hanisch M Karasmann B Schneider, Arzneim -Forsch/Drug Res 2004 54 456 466
71. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study. K Schumacher B Schneider G Reich T Stiefel G Stoll PR Bock J Hanisch J Beuth, Anticancer Res 2003 23 5081 5088 14981970
72. Postoperative komplementäre Therapie des primären Mammakarzinoms mit lektinnormiertem Mistelextrakt -eine epidemiologische, multizentrische retrolektive Kohortenstudie. K Schumacher B Schneider G Reich T Stiefel G Stoll PR Bock J Hanisch J Beuth, Dtsch Zschr Onkol 2002 34 106 114 10.1055/s-2002-35141 (Pubitemid 38168178)
73. Mistletoe and Gemcitabine in patients with advanced cancer: A model for the phase I study of botanicals and botanical-drug interactions in cancer therapy. PJ Mansky J Grem DB Wallerstedt BP Monahan MR Blackman, Integr Cancer Ther 2003 2 345 352 10.1177/1534735403259061 14713326 (Pubitemid 37444430)
74. Multicenter open labeled clinical study in advanced breast cancer patients. A preliminary report. MM Mahfouz HA Ghaleb MR Hamza L Fares L Moussa A Moustafua A El-Za Wawy L Kourashy L Mobarak S Saed F Fouad O Tony A Tohamy, Journal of the Egyptian Nat Cancer Inst 1999 11 221 227
75. Significant tumor reduction, improvement of pain and quality of life and normalization of sleeping patterns of cancer patients treated with a high dose of mistletoe. MM Mahfouz HA Ghaleb A Zawawy A Scheffler, Ann Oncol 1998 9 129 9553655
76. Mistel-Lektin bei Patienten mit Tumorerkrankungen. A Finelli R Limberg, Medizin im Bild Diagnostik und Therapie im Bild 1998 1 1 8
77. Neoadjuvant treatment in HPV-related CIN with Mistletoe preparation (Iscador). E Portalupi, Dissertation Universität Pavia 1991/1992 1995
78. Zur Therapie des malignen Pleuraergusses mit einem Mistelpräparat. H Werner MM Mahfouz L Fares F Fouad HA Ghaleb MR Hamza L Kourashy AL Mobarak A Moustafa S Saed O Zaky A Zawawy S Fischer R Scheer A Scheffler, Der Merkurstab 1999 52 298 301
79. Intrapleurale Instillation eines Extraktes aus Viscum album [L.] zur Behandlung maligner Pleuraergüsse. C Stumpf M Schietzel, Tumordiagnose u Therapie 1994 57 62
80. Intraperitoneal instillation of Viscum album (L.) extrat (mistletoe) for therapy and malignant ascites. Unpublished. Department of Radiology/Oncology, Community Hospital of Herdecke, University Witten/Herdecke. UKH Friedrichson, 1995 8529405
81. Human cancer cells exhibit in vitro individual receptiveness towards different mistletoe extracts. F Knöpfl-Sidler A Viviani L Rist A Hensel, Pharmazie 2005 60 448 454 15997835
82. 2-Herstellung, Analytik, Wirkung in vitro. T Zuzak L Rist A Viviani J Eggenschwiler C Mol U Riegert U Meyer, Der Merkurstab 2004 57 467 473
83. Keine Stimulation in vitro kultivierter Tumorzellen durch Mistellektin. A Büssing D Schietzel M Schietzel M Schink GM Stein, Dtsch Zschr Onkol 2004 36 66 70 10.1055/s-2004-828263 (Pubitemid 39005883)
84. No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extrakt in vitro. AM Burger U Mengs G Kelter JB Schüler HH Fiebig, Anticancer Res 2003 23 3801 3806 14666680
85. 2interact with the cell cycle machinery and target survival mechanisms in cancer cells. FC Ramaekers M Harmsma KJ Tusenius B Schutte M Werner M Ramos, Medicina 2007 67 79 84
86. Differential effects of Viscum album extract IscadorQu on cell cycle progression and apoptosis in cancer cells. M Harmsma M Gromme M Ummelen W Dignef KJ Tusenius FC Ramaekers, Int J Oncol 2004 25 1521 1529 15547686
87. Effects of mistletoe (Viscum album L.) extracts Iscador on cell cycle and survival of tumor cells. M Harmsma M Ummelen W Dignef KJ Tusenius FC Ramaekers, Arzneimittelforschung 2006 56 474 482 16927529
88. Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro. G Kelter HH Fiebig, Arzneimittelforschung. 2006 56 6A 435 440 16927523
89. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. G Maier HH Fiebig, Anti-Cancer Drugs 2002 13 373 379 10.1097/00001813-200204000-00006 11984083 (Pubitemid 34454723)
90. Vergleichende Zytotoxizitätsstudien von Viscotoxin-Isoformen und Röntgenstruktur von Viscotoxin A3 aus Mistelextrakten. B Kahle J Debreczeni GM Sheldrick A Zeeck, Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung Essen, KVC Verlag, Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, 2005 83 98
91. Cell biological investigations on the use of mistletoe lectins in cancer therapy. D Mukthar U Pfüller AG Tonevitsky K Witthohn U Schumacher, COST 98. Effects of antinutrients on the nutritional value of legume diets Luxembourg, Office for Official Publications of the European Communities, Bardocz S, Pfüller U, Pusztai A, 1998 187 193
92. Potentiation of tumor necrosis factor - induced apoptosis by mistletoe lectin. H-O Pae W-G Seo G-S Oh M-K Shin H-S Lee HS Lee SB Kim H-T Chung, Immunopharmacology and Immunotoxicology 2000 22 697 709 10.3109/ 08923970009016433
93. Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro. AM Burger U Mengs JB Schüler HH Fiebig, Arzneimittelforschung 2001 51 9 748 757 11642008
94. Cytotoxic activity and absence of tumor growth stimulation of standardized mistleteo extracts in human tumor models in vitro. G Kelter JM Schierholz IU Fischer H-H Fiebig, Anticancer Res 2007 27 223 233 17352237
95. Viscum album extracts Iscador P and Iscador M counteract the growth factor induced effects in human follicular B-HNL cells and breast cancer cells. F Hugo S Schwitalla B Niggemann KS Zänker KEJ Dittmar, Medicina 2007 67 90 96
96. Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model. J Beuth HL Ko H Schneider S Tawadros HU Kasper H Zimst JM Schierholz, Anticancer Res 2006 26 4451 4456 17201168
97. Zur direkten Zytotoxizität von Mistelpräparaten. A Scheffler HH Fiebig D Kabelitz HR Metelmann, Erfahrungsheilkunde 1993 338 346
98. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. H-J Gabius F Darro M Remmelink S Andre J Kopitz A Danguy S Gabius I Salmon R Kiss, Cancer Investigation 2001 19 114 126 10.1081/CNV-100000146 11296616 (Pubitemid 32236689)
99. Toxicity of mistletoe lectins I, II and III on normal and malignant cells. J Kopp I-J Körner U Pfüller W Göckeritz R Eifler K Pfüller H Franz, Lectins: Biology, Biochemistry, Clinical Biochemistry Hellerup (Denmark), Textop, Van Driessche E, Franz H, Beeckmans S, Pfüller U, Kallikorm A, Bog-Hansen TC, 1993 8 41 47
100. Cell-mediated and direct cytotoxicity of purified ingredients of Viscum album. H Wagner E Jordan KS Zänker, J Cancer Res Clin Oncol 1987 53
101. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. S Abuharbeid J Apel M Sander B Fiedler M Langer ML Zuzarte F Czubayko A Aigner, Biochem Biophys Res Commun 2004 321 403 412 10.1016/j.bbrc.2004.06.160 15358191
102. Stellenwert, Dosierung und Gefährlichkeit (Tumorenhancement) des ML I -immunologische Schlufolgerungen und experimentelle Untersuchungen. GS Kienle H Kiene, Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen Stuttgart, New York, Schattauer Verlag 2003 301 332
103. The in vivo toxicity of toxic lectins is a complex phenomenon. H Franz, Lectins: Biology, Biochemistry, Clinical Biochemistry Hellerup (Denmark), Textop, Van Driessche E, Franz H, Beeckmans S, Pfüller U, Kallikorm A, Bog-Hansen TC, 1993 8 5 9
104. Inhibitory effects of a protein complex from Viscum album on fibroblasts and HeLa cells. O Klamerth F Vester G Kellner, Hoppe Seylers Z Physiol Chem. 1968 349 6 863 864 5722830
105. Isolation of Viscotoxins -Cytotoxic basic polypeptides from Viscum album L. J Konopa JM Woynarowski M Lewandowska-Gumieniak, Hoppe Seylers Z Physiol Chem 1980 361 10 1525 1533 7450674 (Pubitemid 11177768)
106. Reaktion der In-vitro-Kulturen von menschlichen Fibroblasten, HeLa-Zellen und von murinen L-Zellen bei Applikationen eines Präparats aus Viscum album L. W Ulrich F Mechelke, Arzneim -Forsch/Drug Res 1980 30 II 1722 1725
107. Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. M Jurin N Zarkovic M Hrzenjak Z Ilic, Oncology 1993 50 393 398 10.1159/000227217 8233280
108. Comparison of the effects of Viscum album lectin ML-1 and fresh plant extract (Isorel) on the cell growth in vitro and tumorigenicity of melanoma B16F10. N Zarkovic T Kalisnik D Kissel M Konitzer M Jurin S Grainza, Cancer Biother Radiopharm 1998 13 121 131 10.1089/cbr.1998.13.121 10850348
109. Flow cytometric Analysis of human cell lines after exposure to preparations from Viscum album. B Fritz W Ulrich, Planta Med 1989 55 100 101 10.1055/s-2006-961860
110. Einfluss von Viscum album L. Präparaten und allopathischen Zytostatika auf Proliferation, Zellzyklus und DNA-Gehalt menschlicher Zellen in vitro. B Fritz, PhD Thesis Universität Hohenheim 1989
111. Anticancer activity of plant extracts. A Taylor GF McKenna HM Burlage, Texas reports on Biology and Medicine 1956 14 538 556
112. Mistletoe lectins and their A and B chains. H Franz, Oncology 1986 43 23 34 10.1159/000226417 3543782
113. ber die Wirkung von Mistelextrakten (Iscador und Plenosol). PG Seeger, Erfahrungsheilkunde 1965 14 149 174
114. Tumor inhibitory activity of products of Loranthaceae (mistletoe). OS Selawry MR Schwartz H Haar, Proceedings of the American Association for Cancer Research 1959 62 63
115. Die kanzerostatischen Wirkungen spezieller Viscum-Proteine -Signifikanz und Wirkungsverlust. G Snajberk, PhD Thesis Ludwig-Maximilians-Universität, München 1980
116. Direct cytotoxicity effects of preparations used as unconventional methods in cancer therapy in human tumor xenografts in the clonogenic assay and in nude mice. M Drees DP Berger WA Dengler GH Fiebig, Immunodeficient animals: Models for cancer research Basel, Karger Verlag, Arnold W, Köpf-Maier P, Micheel B, 1996 51 115 122
117. An overview on anticancer activities of the Viscum album extract Isorel. N Zarkovic T Vukovic I Loncaric M Miletic K Zarkovic S Borovic A Cipak S Sabolovic M Konitzer S Mang, Cancer Biother Radiopharm 2001 16 55 62 10.1089/108497801750096041 11279798
118. Immunomodulation by the Viscum album L. preparation Isorel and its antitumorous effects. M Jurin N Zarkovic S Borovic D Kissel, Grundlagen der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung Stuttgart, Hippokrates Verlag GmbH, Scheer R, Becker H, Berg PA, 1996 315 324
119. Recent studies on the anticancer activities of Mistletoe (Viscum album) and its alcaloids. TA Khwaja CB Dias S Pentecost, Oncology 1986 43 42 50 10.1159/000226419 3543783
120. Cytotoxic effects of the Viscum album L. extract on Ehrlich tumour cells in vivo. T Cebovic S Spasic M Popovic, Phytotherapy Research 2008 22 1097 1103 10.1002/ptr.2464 18570233
121. Tumoricidal activity of mouse peritoneal macrophages treated with Viscum album extract. G Kuttan, Immunological Investigations 1993 22 431 440 10.3109/08820139309063421 8262566
122. Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. G Kuttan R Kuttan, Cancer Lett 1992 123 130 10.1016/0304-3835(92)90224-J 1394116
123. Effect of a preparation from Viscum album on tumor development in vitro and in mice. G Kuttan V Kuttan R Kuttan, Journal of Ethnopharmacology 1990 29 35 41 10.1016/0378-8741(90)90095-B 2345458
124. Studies on the tumor-inhibiting efficacy of Iscador in experimental animal tumors. M Berger D Schmähl, J Cancer Res Clin Oncol 1983 262 265 10.1007/BF00395755 6853588
125. Experimentelle Untersuchungen über lokale Beeinflussung von Impfgeschwülsten. FE Koch, Z Krebsforsch 1938 325 335
126. Experimentelle Untersuchungen über entzündung- und nekroseerzeugende Wirkung von Viscum album. FE Koch, Z Ges Exp Med 1938 103 740 749 10.1007/BF02609253
127. Mistletoe preparations prevent changes in copper metabolism which normally occur in rats with implanted tumors. Abstract 18. Proceedings from the 73rd Annual Meeting of the American Association for Cancer Research -April 28-May 1, 1982. MC Linder C Murillo, St. Louis, Missouri 1982 5
128. Die Wirkung von Iscador (Viscum praeparatum M.) auf das Walker-Karzinosarkom der Ratte. W Seitz, Wien Klin Wochenschr 1975 87 131 132 1130081
129. Recombinant mistletoe lectin (ML) is a potent inhibitor of tumor cell growth in vitro and in vivo. AM Burger U Mengs JB Schüler H Zinke H Lentzen HH Fiebig, Proceedings of the American Association for Cancer Research 1999 40 399
130. Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination. effects on tumour growth, capillary leakage and nitric oxide (NO) production. AV Timoshenko Y Lan H-J Gabius PK Lala, Eur J Cancer 2001 37 1910 1920 10.1016/S0959-8049(01)00156-3 11576848 (Pubitemid 32913320)
131. Viscaceae lectins. H Franz, Advances in lectin research Berlin, Volk und Gesundheit, Franz H, 1989 2 28 59
132. ber die kanzerostatischen und immunogenen Eigenschaften von Mistelproteinen. F Vester, Krebsgeschehen 1977 5 106 114
133. Verfahren zur Gewinnung eines Arzneimittels. J Müller, (C 24971 IVa/30h), 1-12. 24-5-1962. Bundesrepublik Deutschland
134. Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice. U Schumacher S Feldhaus U Mengs, Cancer Lett 2000 150 171 175
135. Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador). R Ziegler R Grossarth-Maticek, eCam 2008 18955332
136. Validation of the self-regulation questionnaire as a measure of health in quality of life research. A Büssing M Girke C Heckmann F Schad T Ostermann M Kröz, Eur J Med Res 2009 14 5 223 227 19541580
137. Randomized and double-blind studies -demands and reality as demonstrated by two examples of mistletoe research. M Rostock R Huber, Forsch Komplementarmed Klass Naturheilkd. 2004 11 Suppl 18 22 10.1159/000080571 (Pubitemid 39279365)
138. Placebo Effects in Oncology. G Chvetzoff I Tannock, J Natl Cancer Inst 2003 95 19 29 12509397
139. The powerful placebo effect. Fact or fiction? GS Kienle H Kiene, J Clin Epidemiol 1997 50 1311 1318 10.1016/S0895-4356(97)00203-5 9449934 (Pubitemid 28034984)
140. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. A Hrbjartsson P Gøtzsche, N Engl J Med 2001 344 1594 1602 10.1056/NEJM200105243442106 11372012 (Pubitemid 32479913)
141. Mistletoe treatment in cancer-related fatigue: a case report. K Wode T Schneider I Lundberg GS Kienle, Cases Journal 2009 2 77 19161607 10.1186/1757-1626-2-77
142. Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. R Stone A Richardson E Ream AG Smith DJ Kerr N Kearney, Ann Oncol 2000 11 971 975 10.1023/A:1008318932641 11038033 (Pubitemid 30739910)
143. Pharmacologic treatment of cancer-related fatigue. JK Carroll S Kohli KM Mustian JA Roscoe GR Morrow, Oncologist 2007 12 43 51 10.1634/theoncologist.12- S1-43 17573455
144. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. KM Mustian GR Morrow JK Carroll CD Figueroa-Moseley P Jean-Pierre GC Williams, Oncologist 2007 12 51 67 10.1634/theoncologist.12-S1- 52 17227900
145. Intention-to-treat analysis and the goals of clinical trials. LB Sheiner DB Rubin, Clin Pharmacol Ther 1995 57 6 15 10.1016/0009-9236(95)90260-0 7828382
146. Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. S Pampallona E von Rohr B van Wegberg J Bernhard S Helwig P Heusser C Huerny H Schaad T Cerny, Onkologie 2002 25 165 170 10.1159/000055227 12006768 (Pubitemid 34507666)
147. Randomized, controlled trials, observational studies, and the hierarchy of research designs. J Concato N Shah RI Horwitz, N Engl J Med 2000 342 1887 1892 10861325 10.1056/NEJM200006223422507 (Pubitemid 30419054)
148. A comparison of observational studies and randomized, controlled trials. K Benson AJ Hartz, N Engl J Med 2000 342 1886 10.1056/NEJM200006223422506 (Pubitemid 30419053)
149. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. R Kunz AD Oxman, BMJ. 1998 317 167 1185 1190 9794851
150. External validity of randomised controlled trials: "To whom do the results of this trials apply?". PM Rothwell, Lancet 2005 365 82 93 10.1016/S0140-6736(04)17670-8 15639683 (Pubitemid 40082150)
151. Impact of mistletoe lectin binding in breast cancer. P Fritz J Dippon T Kierschke I Siegle A Mohring A Moisa TE Murdter, Anticancer Res 2004 24 1187 1192 15154645
152. Modulation of mistletoe (Viscum album L.) lectins cytotoxicity by carbohydrates and serum glycoproteins. M Frantz M-L Jung G Ribéreau-Gayon R Anton, Arzneimittelforschung. 2000 50 5 471 478 10858875
153. Isolation and characterization of Viscumin, a toxic lectin from Viscum album L. (mistletoe). S Olsnes F Stripe K Sandvig A Pihl, The Journal of Biological Chemistry 1982 257 13263 13270 7142144 (Pubitemid 13188940)
154. Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. G Seifert P Jesse A Längler T Reindl M Lüth S Lobitz G Henze A Prokop HN Lode, Cancer Lett 2008 264 218 228 10.1016/j.canlet.2008.01.036 18314258
155. Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model. A Thies P Dautel A Meyer U Pfuller U Schumacher, Br J Cancer 2008 98 106 112 10.1038/sj.bjc.6604106 18026191
156. Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins. IF Pryme S Bardocz A Pusztai SW Ewen, Histol Histopathol 2006 21 285 299 16372250
157. Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. M Rostock R Huber T Greiner P Fritz R Scheer J Schueler HH Fiebig, Anticancer Res 2005 25 1969 1975 16158932
158. Inhibition of lung metastasis by adoptive immunotherapy using Iscador. S Antony R Kuttan G Kuttan, Immunological Investigations 1999 28 1 8 10.3109/08820139909022718 10073677
159. Role of natural killer cells in Iscador mediated inhibition of metastasis by apoptive immunotherapy. S Antony R Kuttan G Kuttan, Immunological Investigations 2000 29 219 231 10.3109/08820130009060863 10933606
160. BA Teicher ed, Tumor models in cancer research Totowa, New Jersey: Humana Press 2001
161. Immunotherapy of human cancer: lessons from mice. PK Srivastava, Nature Immunology 2000 1 363 366 10.1038/80795 11062489
162. Mouse models in oncogenesis and cancer therapy. MV Céspedes I Casanova M Parrẽo R Mangues, Clin Transl Oncol 2006 8 318 329 10.1007/s12094-006-0177-7 16760006
163. Adverse effects during therapy with mistletoe extracts. GM Stein PA Berg, Mistletoe. The Genus Viscum Amsterdam, Hardwood Academic Publishers, Büssing A, 2000 195 208
164. Anaphylaxis to viscotoxins of mistletoe (Viscum album) extracts. C Bauer T Oppel F Rueff B Przybilla, Ann Allergy Asthma Immunol 2005 94 86 89 15702822
165. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). N Hutt M Kopferschmitt-Kubler J Cabalion A Purohit M Alt G Pauli, Allergol Immunopathol (Madr) 2001 29 201 203 11720654
166. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. R Grossarth-Maticek R Ziegler, Eur J Med Res 2006 11 485 495 17182361